Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Cash (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Change in Cash data on record, last reported at $18.0 million in Q4 2025.

  • For Q4 2025, Change in Cash fell 14.51% year-over-year to $18.0 million; the TTM value through Dec 2025 reached -$19.3 million, up 86.36%, while the annual FY2025 figure was -$19.3 million, 86.36% up from the prior year.
  • Change in Cash reached $18.0 million in Q4 2025 per SNDX's latest filing, up from $8.2 million in the prior quarter.
  • Across five years, Change in Cash topped out at $200.8 million in Q4 2023 and bottomed at -$180.8 million in Q1 2024.
  • Average Change in Cash over 5 years is $983700.0, with a median of $1.4 million recorded in 2022.
  • Peak YoY movement for Change in Cash: tumbled 1975.08% in 2022, then surged 6641.99% in 2023.
  • A 5-year view of Change in Cash shows it stood at $150.5 million in 2021, then tumbled by 98.02% to $3.0 million in 2022, then soared by 6641.99% to $200.8 million in 2023, then plummeted by 89.51% to $21.1 million in 2024, then fell by 14.51% to $18.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $18.0 million in Q4 2025, $8.2 million in Q3 2025, and -$45.4 million in Q2 2025.